JAX and Sanofi team up against cancer

The Jackson Laboratory has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat triple-negative breast cancer and ovarian carcinoma.

“We are excited to collaborate with the Immuno-Oncology group from Sanofi,” says JAX Professor Jacques Banchereau, Ph.D., who is based at the JAX Location in Farmington, CT.

Banchereau applies a genomic technique called long-read isoform profiling to take a genomic “fingerprint” of the proteins found on the surfaces of cells. His approach holds promise for developing more targeted and effective treatments for cancer and other diseases. more